Mechanistic basis and potential therapies for myosin storage myopathy

肌球蛋白贮积性肌病的机制基础和潜在治疗方法

基本信息

批准号：
8502563
负责人：
Sanford I Bernstein
金额：
$ 17.77万
依托单位：
SAN DIEGO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-07-01 至 2015-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8502563
关键词：
Aging Alleles Amino Acids Animal Model Applications Grants Autophagocytosis Biocompatible Materials Biological Biological Assay C-terminal Cardiac Cardiac Myosins Cardiomyopathies Cells Crystallins Defect Degenerative Disorder Desmin Development Disease Disease model Drosophila genus Drosophila melanogaster Effectiveness Electron Microscopy Filament Functional disorder Genes Genetic Genetic Heterogeneity Genetically Modified Animals Goals Heat-Shock Response Hereditary Disease Heterozygote Homozygote Human Human Biology Inclusion Bodies Inclusion Body Myositis Investigation Lead Microscopy Modality Modeling Molecular Molecular Chaperones Molecular Motors Muscle Muscle Fibers Muscle function Mutation Myocardium Myopathy Myosin ATPase Myosin Heavy Chains NIH Program Announcements Nature Nemaline Myopathies Organism Pathology Pathway interactions Patients Performance Pharmacotherapy Phenotype Physiological Point Mutation Population Process Property Protein Isoforms Proteolysis Reporting Research Skeletal Muscle Staining method Stains Stress Structure System Testing Therapeutic Transgenic Organisms Vesicle animal model development base design disease phenotype gene therapy heart function human data human disease improved insight interest multicatalytic endopeptidase complex muscular structure mutant myosin storage myopathy novel prevent protein aggregate protein aggregation protein misfolding response retinal rods small molecule therapy design

项目摘要

DESCRIPTION (provided by applicant): We propose to build and analyze the first reported animal models of myosin storage myopathy (MSM), a degenerative disease of human skeletal and cardiac muscles that arises from point mutations in the C-terminal rod region of slow/beta-cardiac myosin heavy chain. Our transgenic Drosophila melanogaster models will be used to dissect the molecular and developmental bases of MSM and to test possible therapeutic modalities. The Drosophila system will allow us to examine both homozygotes and heterozygotes (mutant/+) for each MSM allele in a standardized genetic background. This will define the importance of interactions between wild- type and mutant myosin molecules to disease pathology and will obviate genetic heterogeneity that leads to phenotypic variability in the human disease. We will test the hypotheses that: 1) MSM mutant myosin expressed in Drosophila leads to specific cell biological and physiological abnormalities similar to those seen in human MSM patients, 2) MSM myosin molecules a) are defective in filament assembly, b) show abnormal filament degradation and/or c) are prone to aggregation, 3) preventing MSM myosin aggregate formation or enhancing MSM myosin turnover can improve mutant muscle structure and performance. To test these hypotheses, we will pursue the following specific aims: 1) Examine the structural and functional effects of four different MSM mutations on skeletal and cardiac muscles during aging. We will explore the progressive nature of MSM via microscopy and physiological assays and correlate our results with extant human data. 2) Isolate mutant myosin molecules and assess their filament-forming ability, filament stability to proteolysis and aggregation propensity. This will help define the molecular basis of the disease. 3) Attempt to ameliorate disease phenotypes in organisms a) by over-expressing the molecular chaperones alphaB-crystallin, Hsp70, Hsp90 or UNC-45 (all known to aid in myosin folding and/or protection from stress); b) by using small molecule inducers of the heat shock response to more broadly elicit expression of molecular chaperones; c) by using transgenic or pharmacological approaches to induce autophagy as a mechanism to clear myosin aggregates. This multifaceted approach will provide novel insights into the developmental and biophysical bases of MSM and yield potential therapeutic approaches that may be useful for treating MSM and other inclusion body diseases.

描述（由申请人提供）：我们建议建立和分析肌球蛋白储存肌病（MSM）的第一个报道的动物模型，肌病肌病（MSM）是人类骨骼和心脏肌肉的退化性疾病，这是由慢/β-贝塔 - 卡片肌球蛋白重链的C端杆区域中的点突变引起的。我们的转基因果蝇Melanogaster模型将用于剖析MSM的分子和发育碱，并测试可能的治疗方式。果蝇系统将使我们能够在标准化的遗传背景下对每个MSM等位基因的纯合子和杂合子（突变/+）进行检查。这将定义野生型肌球蛋白分子与疾病病理学之间相互作用的重要性，并将消除导致人类疾病表型变异性的遗传异质性。我们将测试以下假设：1）在果蝇中表达的MSM突变肌球蛋白会导致特定的细胞生物学和生理异常与人类MSM患者相似，2）MSM肌球蛋白分子a）在细丝组装中有特点，b）b）表现出异常的塑料和/或c），以防止异常的形式或c）。 MSM肌球蛋白更新可以改善突变体肌肉结构和性能。为了检验这些假设，我们将追求以下特定目的：1）检查衰老过程中四个不同MSM突变对骨骼和心脏肌肉的结构和功能效应。我们将通过显微镜和生理测定法探索MSM的渐进性，并将结果与现存的人类数据相关联。 2）分离出突变体肌球蛋白分子并评估其形成细丝的能力，丝状质量稳定性和聚集倾向。这将有助于定义该疾病的分子基础。 3）试图通过过度表达分子伴侣 - 晶状体，HSP70，HSP90或UNC-45（众所周知，都可以帮助肌球蛋白折叠和/或免受压力保护），试图改善生物体中的疾病表型a）。 b）使用对更广泛的分子伴侣表达的热休克响应的小分子诱导剂； c）使用转基因或药理方法诱导自噬作为清除肌球蛋白骨料的机制。这种多方面的方法将为MSM的发育和生物物理碱提供新的见解，并产生潜在的治疗方法，这些方法可能对治疗MSM和其他纳入身体疾病有用。